The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Preliminary results suggest that anti-CD20 and sphingosine 1-phosphate (S1P) therapies may reduce the antibody response to COVID-19 vaccination.

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. ePoster Abstract # OC48.2

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

The Pharma Data

JANUARY 17, 2021

18, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences (Formerly Known As Taconic Farms, Inc.) Immuno-oncology is a leading research priority because it uses the body’s own immune system to effectively treat some types of cancer. RENSSELAER, N.Y.,

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

The Pharma Data

JANUARY 3, 2021

This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. The topline data from the trial is expected to be available in January 2021. The pharmacokinetics of nasally administered Foralumab will also be evaluated. Dr. .

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S. to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO).

Treatment 52

Treatment Pharmacokinetics Disease Pharmaceutical Companies 52

Drug Target Review

OCTOBER 4, 2023

7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. Existing therapies have been focused on eliminating the cancer cells and/or on preventing its progression by using a combination of chemotherapy, radiotherapy, and surgical approaches.

Research 130

Research Therapies Immune Response Clinical Trials 130